1-3 of 3
Peter Amlot
Close
Sort by
Journal Articles

Phase I Trial of the 131 I-Labelled Anti-CD25 Antibody Basiliximab in the Treatment of Patients with Relapsed or Refractory Lymphoma.

Gairin Dancey, MB, BS, John Violet, PhD, Shokri Othman, BSc, Sweta Parker, MSc, Alan Green, PhD, Surinder Sharma, PhD, Ros Francis, PhD, Natalie Griffin, BSc, Pei-San Chan, BSc, MRPharmS, Peter Amlot, MD, Anmol Malhotra, FRCR, Nicholas Woodward, FRCR, Peter Isaacson, FRCP, Thomas A. Lister, PhD, John Buscombe, MD, Richard Begent, MD, Christopher McNamara, MB, BS
Journal: Blood
Blood (2007) 110 (11): 648.
https://doi.org/10.1182/blood.V110.11.648.648
Published: 2007
Journal Articles

Immunoglobulin heavy-chain gene rearrangement in adult acute lymphoblastic leukemia reveals preferential usage of J H -proximal variable gene segments

Forida Y. Mortuza, Ilidia M. Moreira, Maria Papaioannou, Paula Gameiro, Luke A. Coyle, Clair S. Gricks, Peter Amlot, Hugh Grant Prentice, Alejandro Madrigal, Alan Victor Hoffbrand, Letizia Foroni
Journal: Blood
Blood (2001) 97 (9): 2716–2726.
https://doi.org/10.1182/blood.V97.9.2716
Published: 2001
Journal Articles

Recombinant RFB4 Immunotoxins Exhibit Potent Cytotoxic Activity for CD22-Bearing Cells and Tumors

Elizabeth Mansfield, Peter Amlot, Ira Pastan, David J. FitzGerald
Journal: Blood
Blood (1997) 90 (5): 2020–2026.
https://doi.org/10.1182/blood.V90.5.2020
Published: 1997